These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23277247)

  • 21. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia.
    Macfadden W; Bossie CA; Turkoz I; Haskins JT
    Int Clin Psychopharmacol; 2010 Mar; 25(2):75-82. PubMed ID: 20101185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study.
    De la Gándara J; San Molina L; Rubio G; Rodriguez-Morales A; Hidalgo Borrajo R; Burón JA
    Expert Rev Neurother; 2009 Oct; 9(10):1463-74. PubMed ID: 19831836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 25. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.
    Taylor DM; Young CL; Mace S; Patel MX
    J Clin Psychiatry; 2004 Aug; 65(8):1076-83. PubMed ID: 15323592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.
    Llorca PM; Sacchetti E; Lloyd K; Kissling W; Medori R
    Int J Clin Pharmacol Ther; 2008 Jan; 46(1):14-22. PubMed ID: 18218293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
    Duncan EJ; Woolson SL; Hamer RM
    Int Clin Psychopharmacol; 2012 Sep; 27(5):283-90. PubMed ID: 22644368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Explicit review of risperidone long-acting injection prescribing practice.
    Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
    J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.
    Lambert M; De Marinis T; Pfeil J; Naber D; Schreiner A
    Eur Psychiatry; 2010 May; 25(4):220-9. PubMed ID: 19926263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia.
    Lee MS; Ko YH; Lee SH; Seo YJ; Kim SH; Joe SH; Han CS; Lee JH; Jung IK
    Hum Psychopharmacol; 2006 Aug; 21(6):399-407. PubMed ID: 16915580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
    Peuskens J; Olivares JM; Pecenak J; Tuma I; Bij de Weg H; Eriksson L; Resseler S; Akhras K; Jacobs A
    Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.
    Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):61-8. PubMed ID: 22776632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.
    Macfadden W; Alphs L; Haskins JT; Turner N; Turkoz I; Bossie C; Kujawa M; Mahmoud R
    Bipolar Disord; 2009 Dec; 11(8):827-39. PubMed ID: 19922552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES).
    Dubois V; Peuskens J; Geerts P; Detraux J
    Early Interv Psychiatry; 2014 Feb; 8(1):39-49. PubMed ID: 23343330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients.
    Girardi P; Serafini G; Pompili M; Innamorati M; Tatarelli R; Baldessarini RJ
    Pharmacopsychiatry; 2010 Mar; 43(2):66-72. PubMed ID: 20099224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia.
    Xiang YT; Wang CY; Ungvari GS; Kreyenbuhl JA; Chiu HF; Lai KY; Lee EH; Bo QJ; Dixon LB
    Pharmacopsychiatry; 2011 Jun; 44(4):135-41. PubMed ID: 21710403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
    Arunpongpaisal S; Srisurapanont M; Kongsakon R; Kitiwattanagul K; Samanwongthai U
    J Med Assoc Thai; 2010 Mar; 93(3):343-50. PubMed ID: 20420110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.
    Suzuki H; Gen K
    Hum Psychopharmacol; 2012 Sep; 27(5):470-5. PubMed ID: 23001955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.